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Background: miR-182 is one of the most significantly up-regulated miRNAs in hepatocellular carcinoma (HCC).
Metastasis suppressor 1 (MTSS1), one target gene of miR-182, plays an important role in the metastasis of cancers.
However, it remains unclear what role does function and mechanism of miR-182 and MTSS1play in HCC.
Methods: miR-182 expression was tested in 86 cases of paired HCC and normal tissues by real-time PCR and the
relationships between miR-182 expression and clinicopathological parameters were analyzed. The expression of
MTSS1 was evaluated by immunohistochemistry and western blot in the above tissues and its correlation with
miR-182 expression was analyzed. Moreover, western blot and invasion assays were performed after transfection of
pre-miR-182 or anti-miR-182 to HCC cell lines. In addition, luciferase assays was performed to confirm the regulation
of miR-182 on MTSS1.
Results: Compared with normal tissue, miR-182 was up-regulated and MTSS1 was down-regulated in HCC tissues.
Moreover, the over-expression of miR-182 was correlated with intrahepatic metastasis (p= 0.034) and poor
prognosis (p= 0.039) of HCC patients. There was a negative correlation between miR-182 and MTSS1 expression in
both HCC tissues (r=−0.673, p< 0.01) and HCC cell lines (r=−0.931, p= 0.021). Furthermore, the up-regulation of
miR-182 resulted in the down-regulation of MTSS1 and increased invasive potential of HUH-1, and reverse results
were also confirmed when the expression of miR-182 was inhibited. In addition, the results of the luciferase assay
demonstrated the targeted regulation of miR-182 on MTSS1.
Conclusions: miR-182 could promote metastasis of HCC and inhibit the expression of MTSS1. miR-182 and MTSS1
are potential prognostic markers and/or therapeutic targets in HCC.
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Hepatocellular carcinoma (HCC), one of the most no-
toriously invasive cancers, is among the top 10 most
prevalent cancers worldwide, accounting for ~600,000
deaths annually [1,2]. At present, surgical resection/liver
transplantation is the only treatment modality to confer
survival benefit in HCC patients, and the overall 5-year
survival rate for HCC patients is less than 5% [3]. The
most important reason leading to poor prognosis is intra
hepatic metastasis [4]. It is thus necessary to elucidate* Correspondence: jianwang04@yahoo.com.cn
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reproduction in any medium, provided the orthe molecular mechanisms underlying HCC metastasis
and identify novel therapeutic targets.
Recently, it has been manifested that the deregulation
or dysfunction of miRNAs is involved in cancer develop-
ment and related to clinical outcomes of cancer patients
including HCC [5-12]. Yu, et al reported miR-182 was
one of the most significantly up-regulated miRNA in
HCC patients [13]. Aberrant miR-182 expression pro-
motes melanoma metastasis by repressing FOXO3 and
microphthalmia-associated transcription factor [14,15],
which indicates that miR-182 may promote the metastasis
of HCC through targeting on some genes. In both web-
sites Target scan and Pictar, we found hundreds of target
genes regulated by miR-182. Among those genes with
highly conserved binding sites, metastasis suppressor 1td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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strated to have prognostic value and anti-metastatic prop-
erties in breast cancer [16] and gastric cancer [17].
We then tested the expressions of MTSS1 and miR-
182 in paired normal liver and HCC tissues. Statistics
analysis demonstrated the negative correlation between
miR-182 and MTSS1 and the important clinicopathologi-
cal significance of miR-182 in HCC patients. Experi-
ments in vitro further confirmed that miR-182 can
promote the metastasis of HCC cell lines and down-
regulate MTSS1, which further elucidate the metastatic




Informed consent was obtained from all the patients for
the collection of liver specimens, and the study protocol
was approved by the Ethics Committee of Tianjin Med-
ical University. The investigations were conducted
according to the Declaration of Helsinki Principles. The
clinical pathological data were collected as described in
our earlier study [2]. Eighty-six primary HCC patients
treated in Cancer Hospital of Tianjin Medical University
between 2004 and 2007 were selected according to the
following criteria: (1) The diagnosis of HCC was con-
firmed by pathology; (2) No preoperational chemother-
apy or TAE were performed; (3) All of the samples were
from the hepatectomy for the first time; (4) Incisal mar-
gins were negative; and (5) Clinicopathologic data of the
cases could be collected. Among the 86 patients, there
were 67 men (77.9%) and 19 women (22.1%). The mean
age at diagnosis was 50.7 ± 9.7 years, ranging from 29 to
78 years. HBV was positive in 72 patients (83.7%). The
percentage of AFP (>100 ng/ml) was 80.2%. Moreover,
one tumor was detected in 79.1% (68/86) patients and
multiple tumors (≥2) were found in 20.9% (18/86)
patients with totally 29 metastatic leisions. The average
tumor size was 5.8 ± 2.7 cm (0.4-16 cm). Histologically,
32.6% (28/86), 46.5% (40/86) and 20.9% (18/86) tumors
were grade 1, 2 and 3, respectively. No chemotherapy
was performed after radical resection. Patients were fol-
lowed-up at the outpatient clinic with measurement of
the serum alpha-fetoprotein level and hepatic ultrason-
ography every 2–4 months from the date of initial treat-
ment. The mean time of follow-up was 28.3 months
(range 3– 56 months). When recurrence was suspected,
further evaluations were performed by abdominal com-
puted tomography (CT) scan, if necessary, by ultrasound-
guided biopsy to confirm the diagnosis. Recurrence was
observed in 46.5% (40/86) patients. HCC and non-
neoplastic tissues were collected and stored at −80°C until
analysis. For every frozen tumor tissue, we cut frozen
slide and did HE staining and evaluated the percentageof tumor cells. The percentage of tumor cells was about
90%. In addition, paraffin-embedded HCC tissues were
also collected.
RNA extraction and quantitative RT-PCR for miR-182
Total RNA, including miRNA, was extracted using TRI-
zol reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. Total RNA was
reversely transcribed using the corresponding RT Primer
and the TaqMan MicroRNA Reverse Transcription Kit
(Applied Biosystems). The expression of miR-182 and its
control RNU44 were detected using TaqMan miRNA
assay system (Applied Biosystems, Foster City, CA,
USA). The median miRNA intensity value of 86 patient
samples was used as the threshold, and patients were
divided into two groups (below median, group low miR-
182 and above median, group high miR-182) according
to the expression of miR-182.
Immunohistochemistry staining and evaluation for MTSS1
Immunohistochemistry (IHC) was used to detect MTSS1
expression in paraffin-embedded HCC tissues. Five-μm
sections of paraffin-embedded HCC tissue were baked at
65°C for 2 h, followed by deparaffinization using stand-
ard procedures. After antigen retrieval, MTSS1 antibody
(Cell Signaling Technology, Inc. Danvers, MA, USA)
was applied to slides, followed by the secondary antibody
conjugated with horseradish peroxidase. Signals were
revealed by using the Histostain Plus kit (Invitrogen,
Grand Island, NY, USA) according to the manufacturer's
instruction. 3, 3-Diaminobenzidine (DAB) was used as a
chromogen. The sections were counter-stained with
hematoxylin. We prepared a negative control by substi-
tuting PBS for the antibody.
MTSS1 protein expression was evaluated by two
pathologists. MTSS1-positive samples were defined as
those with brown staining in the cytoplasm. The results
of MTSS1 immunohistochemical analysis were estimated
with semi-quantity method. The staining intensity was
graded on a scale from 0 to 3 (0 for no staining, 1 for
weak immunoreactivity, 2 for moderate immunoreactiv-
ity, and 3 for strong immunoreactivity) The percentage
of immunoreactivity was scored on a scale from 0 to 4
(0, no positive cells; 1, <25% of cells positive; 2, 25%–
50% of cells positive; 3, 50– 75% of cells positive; and 4,
>75% cells positive). Finally, a total score (negative: 0;
weak: 1–2; medium: 3–5; strong: 6–7) was obtained by add-
ing the scores of staining intensity and percentage positivity.
Western blot for MTSS1
Cell lysates were harvested with 2% sodium dodecyl sul-
fate (SDS)-125 mM Tris/HCl (pH 7.4). Cell lysates (25–
30 ug of protein) were resolved in Tris/glycine SDS/PAGE
gels and transferred to PVDF membranes. Membranes
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and incubated with horseradish-peroxidase-coupled sec-
ondary antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). The background was subtracted, and the
signals of the detected bands were normalized to the
amount of loading control β-actin (Cell Signaling Tech-
nology, Inc. Danvers, MA, USA) band. The protein levels
were quantified using ImageJ software (National Institute
of Mental Health, Bethesda, MD, USA. http://rsb.info.nih.
gov/ij).
Cell culture and transfection
Human HCC cell lines HLE, HLF, HepG2, Hep3B and
HUH-1 were obtained from American Type Culture
Collection (Manassas, VA, USA) and cultured in DMEM
(Invitrogen) except HepG2 (MEM) supplemented with
heat-inactivated 10% fetal bovine serum (Invitrogen) at
37°C in a humidified incubator containing 5% CO2.
For transfection, 2 × 105 HLF or HUH-1 cells were
seeded into each well of a 6-well plate and incubated
overnight, then the cells were transfected with Pre-
miR miRNA Precursor Molecule pre-182 (pre-miR-182)
and anti-miR miRNA inhibitor anti-182 (anti-miR-182)
(Applied Biosystems) at a final concentration of 100 nM
using the Lipofectamine 2000 transfection reagent (Invi-
trogen, Carlsbad, CA, USA), according to the manufac-
turer’s instructions. The specificity of the transfection
was verified using the Pre-miR miRNA Precursor Mol-
ecule Negative Control #1 (control pre-miR) and Anti-
miR miRNA Inhibitors Negative Control #1 (control
anti-miR) (Applied Biosystems). The expression levels of
miR-182 and MTSS1 were quantified 24 h after transfec-
tion, and the cells were used for western blot analysis.
3’ UTR luciferase reporter assay
The human MTSS1 3’ UTR luciferase reporter construct
(MTSS1-3’UTR WT) was generated by cloning MTSS1
mRNA 3’UTR sequence into downstream of pMIR-
Report construct (Ambion, Foster City, CA, USA). The
MTSS1 3’ UTR sequence was generated by PCR using
primer MTSS1 3’UTR F SpeI: 5’-AAACTAGTTGATT
TTTCTGAAGGT GCCAAATTCCATTTAA-3’ and primer
MTSS1 3’UTR R SacI: 5’–GGGAGCTCTTTGGCAA
CATTTTATTTATTCA-3’. The miR-182 target site-
mutation MTSS1 3’ UTR luciferase reporter 1 (MTSS1-
3’UTR mutation 1) construct was generated by employing
direct-site mutagenesis using mutation primers which
mutate the miR-182 binding site from TCTGAAGGTGC
CAA to GATGAAGGTCGGTA. miR-182 target site-
mutation MTSS1 3’ UTR luciferase reporter (MTSS1-
3’UTR mutation 2) was mutated from TTGCCAA to
TAACGCT in the miR-182 binding site. MTSS1-3’UTR
mutation 1, 2 was mutated in these two miR-182 bind-
ing sites.HUH-1 cells were co-transfected with miR-182 plas-
mid and wild-type or mutant MTSS1 3’ UTR luciferase
reporter construct and luciferase activities were mea-
sured using the Dual-Glo Luciferase. Data were normal-
ized by dividing Firefly luciferase activity with that of
Renilla luciferase.
In-vitro invasion assays
HLF and HUH-1 cell invasion assays were performed
using 24-well Matrigel Invasion Chambers (BD Bios-
ciences, CA, USA). The lower chambers were filled with
0.75 ml of DMEM medium containing 10% fetal bovine
serum (FBS). A cell suspension of 2 × 105 in 0.5 ml
DMEM medium was added into each well of the upper
chamber. After the cells were incubated for 24 h at 37°C
in a humidified incubator with 5% CO2, The invasive
cells attached to the lower surface of the membrane
insert were fixed in 10% formalin at room temperature
for 5 min and stained with 0.05% crystal violet. The
non-invading cells that remained on the upper surface of
the membrane were removed by scraping. The number
of invasive cells on the lower surface of the membrane
was then counted under a microscope.
Statistical analysis
Differences in MTSS1 immunohistochemical staining
between groups were compared using chi-square or
Fisher exact tests in human samples. The correlation
between MTSS1 expression and miR-182 was evaluated
by calculating the Spearman rank correlation coefficient.
Moreover, mean ± SD of clinicopathological variables
were calculated, and differences in the means were ana-
lyzed using one-way analysis of variance or Student’s t
test. We also used the Kaplan-Meier method and the
log-rank test in univariate survival analysis, and we used
the Cox proportional hazards regression model in our
multivariate analysis. SPSS version 16.0 (IBM) was used
to perform our statistical analysis. Two-tailed P values
< 0.05 were considered statistically significant.
Results
The expression of miR-182 and its correlation with
clinical-pathological features
To investigate the role of miR-182 in HCC development,
we tested the expression of miR-182 in 86 HCC and
matched non-neoplastic tissues (Figure 1A). The relative
expression of miR-182 in HCC samples (2.21 ± 1.29) was
significantly higher than that of matched normal tissues
(1.12 ± 0.47) (p< 0.01) (Figure 1B). Hence, we consid-
ered the up-regulation of miR-182 may contribute to
HCC tumorigenesis. Furthermore, the relative level of
miR-182 in poorly differentiated HCC (3.28 ± 1.79) was
almost one time higher than that in well (1.62 ± 0.68)
and medium differentiated cases (2.14 ± 0.83) (Figure 1B),
Figure 1 Expression of miR-182 in normal and tumor tissues of 86 HCC patients. Relative expression of miR-182 was detected by real time
PCR in every paired normal and HCC tissues (A). The relative expression of miR-182 in HCC tissues (n = 86, 2.21 ± 1.29) was significantly higher
than that of normal liver tissues (1.12 ± 0.47) (B). The relative level of miR-182 in HCC of grade 1, grade 2 and grade 3 were 1.62 ± 0.68, 2.14 ± 0.83
and 3.28 ± 1.79, repectively, which were also significantly higher than that of normal tissues. * p< 0.05; ** p< 0.01.
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the progress of HCC.
For better understanding the potential role of miR-182
in HCC progression, we analyzed its correlation with
some clinicopathological variables including age, sex,
HBV infection, AFP, tumor number, tumor size, expres-
sion of MTSS1, histological grade, portal vein invasion
and recurrent time (Table 1). Based on the median value
(1.92) of miR-182 expression, all patients were divided
into two groups including group with low expression of
miR-182 and group with high expression of miR-182.









Age (<51 years vs ≥51 years) 21:22 25:18 0.387
Gender (male vs female) 35:8 32:11 0.436
HBV (positive vs negative) 37:6 35:8 0.341
AFP(<100 ng/ml vs ≥100 ng/ml) 10:33 7:36 0.417
Tumor number (n< 2 vs n≥ 2) 38:5 30:13 0.034
Tumor size (<5 cm vs ≥5 cm ) 16:27 19:24 0.510
MTSS1 (positive vs negative) 21:22 16:27 0.115
Tumor grade (1 vs 2, 3) 16:27 12:31 0.174
Portal vein invasion (no vs yes) 34:9 27:16 0.096
Recurrent (no vs yes) 28:15 18:25 0.031
AFP: α-fetoprotein.and higher recurrence (p= 0.031) tended to occur in
the patients with high expression of miR-182. Though
the p values did not reach statistical significance,
the patients with high expression of miR-182 had a ten-
dency to undergo occur portal vein invasion (p= 0.096)
(Table 1).
The recurrent percentage is 46.5% (40/86) for all
patients. The median disease-free survival time in group
with low miR-182 and group with high miR-182 was
27.0 months and 24.0 months, respectively. The
Kaplan–Meier method revealed that higher miR-182
expression level correlated with significantly reduced
disease-free survival (42.0 ± 2.93 months in group with
low miR-182 versus 31.2 ±2.79 months in group with
high miR-182, p= 0.039) (Figure 2). Multivariate survival
analysis revealed that multiple tumors (p= 0.023) and
high expression of miR-182 (p= 0.022) were significantly
correlated with the poor prognosis of HCC patients
(Table 2). The result further indicated the importance of
miR-182 up-regulation in HCC development.
The expression of MTSS1 is down-regulated and
negatively correlated with miR-182 in HCC
MTSS1 protein expression was tested with IHC in HCC
and paired normal tissues (for some cases, there are
tumor and adjacent normal tissue in the same slide).
MTSS1 was positive in the cytoplasm of tumor and nor-
mal liver cells. MTSS1 was often highly expressed in
normal tissue (Figure 3 A, B and E), while drastically
reduced MTSS1 expression was shown in the tumor
Figure 2 Univariate analysis of disease-free survival for miR-182 expression in 86 HCC patients. The median value (1.92) of miR-182 level
was chosen as the cutoff point for separating miR-182 low-expression tumors (n = 43) from miR-182 high-expression cases (n = 43). p-value was
shown with the use of log-rank test in SPSS 11.5. p= 0.039 (Kaplan–Meier log-rank survival analyses).
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in 79% (68/86) of normal tissue and in 43% (37/86) of
HCCs (43%). The rate of MTSS1 positive case in HCC
was significantly lower than that in paired normal tissue
(p< 0.001, Figure 3G). Among the 37 cases with MTSS1
positive expression, 13 (35%), 17 (46%) and 7 (19%) cases
showed weak, mederate and strong expression of
MTSS1, respectively. Moreover, no difference of MTSS1
expression was found among the multiple lesions in the
same patient. The MTSS1 positive rate in metastatic
HCC (17%, 3/18) was significantly lower than that in
non-metastatic HCC (50%, 34/68) (p< 0.001, Figure 3G).
In addition, the tumor thrombus in small hepatic vein
also showed low expression of MTSS1 (Figure 3 F).
For the MTSS1 positive cases tested by IHC, the
examination of Western Blot were further performed
and the expressions were quantified (Figure 4 A). Nega-
tive correlation between the expression of miR-182 andTable 2 Multivariate Cox regression analysis for disease-
free survival in 86 HCC patients
Variables HR (95% CI) p
Age (≥51 years vs <51 years) 0.762 (0.683-2.701) 0.383
Gender (female vs male) 0.525 (0.612-2.905) 0.469
HBV (positive vs negative) 0.078 (0.365-2.129) 0.780
AFP (≥100 ng/ml vs <100 ng/ml) 0.884 (0.553-5.397) 0.347
Tumor number (n≥ 2 vs n< 2) 5.132 (1.119-4.727) 0.023
Tumor size (≥5 cm vs <5 cm) 0.497 (0.392-1.554) 0.481
Tumor grade (2,3 vs 1) 0.251 (0.571-2.574) 0.616
Portal vein invasion (yes vs no) 2.824 (0.901-3.872) 0.093
miR-182expression (high vs low) 4.560 (1.073-5.201) 0.033
MTSS1 (negative vs positive) 3.109 (0.225-1.082) 0.078that of MTSS1 in HCC was indicated in Figure 4 B
(r=−0.673; p< 0.01), which suggested MTSS1 maybe
one important functional protein contributing to the
oncogenic role of miR-182. Meanwhile, the negative
correlation between miR-182 and MTSS1 expression
were also found in HCC cell lines (r=−0.931, p= 0.021)
(Figure 4 C and D).
miR-182 promotes invasion and inhibits MTSS1
Next, we sought to investigate the molecular mechanism
responsible for the oncogene effect of miR-182 on HCC
observed above. As miRNAs function mainly through
inhibiting their target mRNAs by binding to the 3’ UTR,
we searched the putative target genes of miR-182 in
Target Scan and Pictar. In both websites, 841 and 702
conserved targets were found, respectively. Among those
targets, human MTSS1, known to have critical roles in
the inhibition of cancer metastasis, contained two puta-
tive conserved miR-182 binding sites with high context
scores (Figure 5A). To verify whether MTSS1 was a dir-
ect target of miR-182, a dual-luciferase reporter system
was used by co-transfection of miR-182 and a luciferase
reporter plasmid containing the 3’ UTR of human
MTSS1 into HUH-1. As shown in Figure 5B, the lucifer-
ase activity was significantly inhibited by miR-182
co-transfection, mutation either of the two miR-182 bind-
ing site, while miR-182 failed to inhibit the expression of
luciferase construct with both binding sites mutated, sug-
gesting that miR-182 could directly target on the 3’ UTR
of MTSS1.
As one target gene of miR-182 demonstrated above,
the expression of MTSS1 was down-regulated in HUH-1
with transfected miR-182 and up-regulated in HLF with
transfected anti-miR-182 (Figure 6 A). An in vitro
Figure 3 Immunohistochemistry staining for MTSS1 in HCC and paired normal tissues (200×). A: Normal (non-neoplastic) liver tissue; B
and C: positive expression of MTSS1 in well-(B) and moderate-(C) differentiated tumors. D: poorly differentiated cancer cells without MTSS1
expression (long arrow) infiltrated into normal liver cell panel with MTSS1 high expression (short arrow); E: MTSS1 expression was lower in the
tumor foci (arrow) compared with around non-neoplastic liver tissue; F: MTSS1 expression is low in tumor thromboses (short arrow) and primary
HCC (long arrow). G: The positive rate of MTSS1 in HCC tissues (43%) was significantly lower than that of normal tissues (79%). Furthermore, the
positive rate (17%) in patients with metastasis (tumor number ≥2) was significantly lower than that of cases without metastasis (50%). ** p< 0.01.
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HLF transfected with anti-miR-182 was specifically
reduced by approximately 41% (p< 0.05) and the rela-
tive invasiveness cells of HUH-1 transfected with miR-
182 was increased by approximately 36% (p< 0.05)
(Figure 6B). The result in vitro further demonstrated
that miR-182 could promote metastasis of HCC and
inhibited the expression of MTSS1.
Discussions
Up-regulation of miR-182 was suggested to exist in a
large part of HCC tissues [15]. In our HCC cases withcomplete clinical data, we also found the up-regulation
of miR-182 and its up-regulation was significantly asso-
ciated with intrahepatic metastasis (tumor number ≥ 2)
and early recurrence, which is an important clinical deter-
minant for the prognosis of HCC patients. Up-regulation
of miR-182 was further suggested to correlate with reduced
disease-free survival of HCC patients. Hence, determin-
ation of miR-182 expression level in HCC tissues may be
a novel approach to predict and identify the prognosis of
HCC patients.
Although miRNA profile did reveal very prospective
features in cancer, the functions and real targets of
Figure 4 Correlation between miR-182 and MTSS1 expression in HCC tissues and cell lines. A: Relative expression of miR-182 was
detected by real time RT-PCR and MTSS1 expression was tested with Western blot and quantified with ImageJ software in 5 paired HCC and
normal tissues. B: There was a negative correlation between miR-182 and MTSS1 expression (n = 37). C: The expression of miR-182 is high and
MTSS1 expression is low in HLF and HLE, whereas Hep-G2 and HUH-1 showed low expression of miR-182 and high expression of MTSS1. D: The
expression of MTSS1 was negatively correlated with miR-182 expression in HCC cell lines. N: normal tissue; T: tumor.
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the majority of microRNAs based on sequence homology
remained to be comprehensively validated by in vitro
and in vivo experiments. Target scan and Pictar showedFigure 5 miR-182 directly targets human MTSS1. A: 3’-UTR region of M
Pictar analysis revealed two miR-182 binding sites in MTSS1 UTR sequence.
Luc- MTSS1-3’UTR mutation. The assay was done in HUH-1 cells as describe
measured with the Dual-Luciferase Reporter system (Promega) 24 h after tr
expression for each sample. Each experiment was performed in triplicate. Dmetastasis suppressor 1 (MTSS1) is one important target
of miR-182 with a high context score. Meanwhile, we
found its expression in HCC decreased significantly com-
pared to that of adjacent normal tissue and negativelyTSS1 mRNA is partially complementary to miR-182. Target-Scan and
B: Effect of miR-182 on the luciferase activity of Luc-MTSS1-3’UTR and
d in Materials and Methods. Renilla and firefly luciferase activities were
ansfection. Firefly luciferase activity was normalized to Renilla luciferase
ata are shown as mean± s.d. *p< 0.01.
Figure 6 miR-182 modulated the expression of MTSS1 and the cells invasive potential of HLF and HUH-1. A: the expression of MTSS1
was up-regulated in HLF and down-regulated in HUH-1 after transfection of anti-miR-182 and pre-miR-182, respectively. Cell invasion assay in HLF
and HUH-1 cells were first transfected with anti-mir-182 and pre-mir-182, respectively or negative control and then subject to matrigel chamber
assays, as described in Materials and Methods. After 24 h, invasion cells were counted after staining with crystal violet. *p< 0.05, **p< 0.01.
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cated MTSS1 maybe the regulation target of miR-182.
MTSS1, also known as MIM (missing in metastasis),
was originally identified by Lee et al. [18] as a potential
metastasis suppressor gene that was present in non-
metastatic bladder cancer cell lines, but was not expressed
in a metastatic bladder cancer cell line [19]. This gene,
mapped to human chromosome 8q24.1, encodes a 5.3 kb
mRNA and a polypeptide predicted to be an actin-binding
protein of 356 amino acids with homology to the WASp
(Wiscott-Aldrich Syndrome protein) family [20]. Func-
tional analyses of MTSS1 have shown thatMTSS1 induced
actin-rich protrusions resembling microspikes and lamelli-
podia at the plasma membrane and promoted disassembly
of actin stress fibres [21]. Actin filament assembly is asso-
ciated with cytoskeletal structure organization and many
forms of cell motility [22]. These data have suggested that
MTSS1 protein may be important in regulating cytoskel-
etal dynamics, and as a consequence it would play a
potential role in the invasion and metastatic behavior of
cancer cells. Therefore, the down-regulation of MTSS1
potentiated by the up-regulation of miR-182 may further
aggravate the epigenetic changes in HCC. We then
focused on the mechanisms that whether the up-regula-
tion of miR-182 mediates the inhibition of MTSS1 and
induced epigenetic alterations in HCC pathogenesis.
miR-182 can bind to MTSS1 at two conserved sites
with a high context score. Our luciferase assay in HCCcell lines demonstrated MTSS1 can be regulated directly
by miR-182. The interesting results in HCC cell lines
is that cells with high invasive ability showed higher
expression level of miR-182 than those with low invasive
potential, which is inversely related with the expression
of MTSS1. Analyses on human samples reinforced the
relevance of miR-182 regulation on MTSS1 in HCC by
revealing an inverse correlation between their expres-
sions. Considering the characteristic heterogeneity of
HCC and that MTSS1 is regulated by additional
mechanisms, a statistically significant association with
miR-182 is especially remarkable. The ability of MTSS1
over-expression to counteract miR-182’s pro-invasion
effects unequivocally shows the importance of this
inverse relationship in HCC metastasis. The functional
analysis of miR-182 together with MTSS1 in animal
models will particularly further evaluate their metastatic
role and show us the clinical treatment value for patients
with HCC. That would be our future research aim.
Concerning the target of miR-182, Miguel and et al.
also reported that the microRNA promotes melanoma
metastasis by repressing FOXO3 and microphthalmia-
associated transcription factor [13]. Together with our
study, it is consistent with current opinions that a single
miRNA can target multiple mRNAs, named ‘targetome’,
to post-transcriptionally regulate gene expression [23].
Hence, it is probable that we are still far from unveiling
the last target of miR-182. According to this presumption,
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the ‘targetome’ and the entire roles of miR-182 in cancer
development. Another important issue is why miR-182 is
up-regulated in HCC and other cancers [15,24]. The
current view suggests that miRNA expression is mainly
controlled at the transcriptional level. A large number of
transcription regulators that influence the transcription
and production of miRNAs have been identified including
Myc, E2F, p53, and STAT3 [25-27]. Another possible
mechanism for the up-regulation of miRNAs in cancer
may result from the amplification of DNA copy number.
Such as miR-182 is one member of a miRNA cluster in a
chromosomal locus (7q31-34) frequently amplified in
HCC [13], the amplification may cause the up-regulation
of miR- 182. This is our future’s research field.
Conclusions
Our study suggests a model of tumor progression in
which elevated miR-182 expression and subsequent down-
regulation of MTSS1 promotes aggressiveness of HCC.
These results suggest that miR-182 and its downstream
effectors could prove to be useful prognostic markers and/
or therapeutic targets in HCC.
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